David Hutton

Eyenovia acquired the US commercial rights for the drug last August from Formosa Pharmaceuticals.

After completing his residency at the Wilmer Eye Institute and a fellowship at NIH, Walter J. Stark, MD, returned to Wilmer for a 40-year career as a surgeon, teacher, researcher, and Boone Pickens Professor of Ophthalmology and chief of the Cornea Division.

During the 2024 American Glaucoma Society meeting held February 29 to March 3 in Huntington Beach, California, Nixoc SA presented posters outlining data on NCX 470.

Mobile cameras allow University of Colorado ophthalmology residents working in hospital settings to conduct more comprehensive and efficient patient evaluations.

David Sola-Del Valle, MD, sat down with David Hutton of Ophthalmology Times to discuss his talk at the annual American Glaucoma Society meeting held in Huntington Beach, about the importance of bridging the language barrier in patients who may not be fluent in English.

April Maa, MD, sat down with David Hutton of Ophthalmology Times to discuss her presentation at the annual American Glaucoma Society meeting held in Huntington Beach, about tips and tricks for implementing telehealth into ophthalmology.

Steven R. Sarkisian, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster about the Travoprost intraocular implant in phakic eyes from the American Glaucoma Society meeting held in Huntington Beach

I. Paul Singh, MD, sat down with David Hutton of Ophthalmology Times to discuss his poster "Travoprost Intraocular Implant Demonstrates Efficacy in Diverse Subpopulations of OAG and OHT Subjects," from the American Glaucoma Society meeting held in Huntington Beach

Leon Herndon, MD, President of the American Glaucoma Society, sat down with David Hutton of Ophthalmology Times to discuss the AGS meeting held in Huntington Beach and what attendees can expect as well as new and exciting information to come from the meeting.

In an annual report, the company revealed the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.

Stargardt disease is an orphan blindness disease that affects approximately 35,000 people in the United States.

According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.

According to the company, 2,500 clinical and peer-reviewed studies that span 235 disease states have demonstrated the clinical utility of Optos technology.

ECP105 has been developed for the recovery of post-surgical treatment of glaucoma.

Prevent Blindness is offering a variety of free educational resources to the public and professionals

Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.

The company will add Pravin U. Dugel, MD, as executive director, and add Jeffrey S. Heier, MD, Peter K. Kaiser, MD, and Sanjay Nayak, PhD, MBBS, to its management team.

The platform streamlines clinical decision workflows, management of teleophthalmology, referral decisions and patient management while improving clinic efficiencies.

Corneal endothelial cells from a single donor tissue could be amplified using Emmecell’s technology to restore vision for hundreds of patients via injectable cell therapy.

Rajendra Apte, MD, PhD, has received the Research to Prevent Blindness /American Macular Degeneration Foundation Catalyst Award for innovative research approaches in studying age-related macular degeneration.

iCRx is set to release the One Minute Eye Exam in April, potentially changing the way ophthalmologists and optometrists conduct eye examinations for corrective lenses.

David Hutton of Ophthalmology Times talks with Kathryn A. Colby, MD, PhD, Elisabeth J. Cohen Professor and Chair, NYU Langone Department of Ophthalmology, about the year the department had in 2023 as well as an outlook at advancements in the field of ophthalmology moving forward.

The free, online event will feature presentations from Rachel Huckfeldt, MD, PhD, and Rachelle Lin, OD.

To speed care, Mount Sinai’s Department of Ophthalmology launched an Eye Stroke Service and developed a treatment protocol for patients.

David Hutton of Ophthalmology Times talks with Taylor Strange, MD, about his time building his practice and implementing the use of the LENSAR ALLY system.

The rule comes as health insurers have increasingly been criticized for onerous and time-consuming prior authorization procedures that physicians say unfairly delay or deny the medical treatment that their patients need

During the tour, the women will participate in Monash University’s Advancing Women in Healthcare Leadership program.

In the next strategic period, The foundation is hoping to scale its programs to make the largest contribution to date. This includes tackling the key barriers to eye health, including chronic workforce shortages across all areas of health, especially in remote regions, and the availability, quality and use of eye health data.

Twelve-week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration.

The funding has been awarded to BIENCO, which is working to cure one of the most common causes of blindness in the world by developing cost effective, individually tailored, superior corneas.